Intravitreal bevacizumab for proliferative diabetic retinopathy: Results from the pan-American collaborative retina study Group (Pacores) at 24 months of follow-up

J. Fernando Arevalo, Andres F. Lasave, Lihteh Wu, Mauricio Maia, Manuel Diaz-Llopis, Arturo A. Alezzandrini, Miguel Brito

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). Methods: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. Results: The mean age of the patients was 55.6 ±11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted. Conclusion: Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.

Original languageEnglish (US)
Pages (from-to)334-343
Number of pages10
JournalRetina
Volume37
Issue number2
DOIs
StatePublished - 2017

Keywords

  • Bevacizumab
  • Diabetic retinopathy
  • Intravitreal injections
  • Proliferative
  • Retinal neovascularization

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Intravitreal bevacizumab for proliferative diabetic retinopathy: Results from the pan-American collaborative retina study Group (Pacores) at 24 months of follow-up'. Together they form a unique fingerprint.

Cite this